Trial results for a study investigating tissue micro-RNA profiles in Pancreatic Adenocarcinoma were posted on ClinicalTrials.gov on 2026-04-16, reporting a mean survival of 8.3 months for patients with solid pancreatic masses.
Background
Pancreatic adenocarcinoma remains a significant global health challenge. Advances in diagnostic techniques, such as endoscopic ultrasonography (EUS), have enabled clinicians to obtain histopathological samples through fine-needle aspiration (FNA) or fine-needle biopsy. These samples offer the opportunity for detailed molecular analysis, including the detection of micro-RNA profiles. Micro-RNAs are small, non-coding RNA molecules that play a role in gene expression. While many studies have focused on seric microRNA profiles, there are also implications for tissue micro-RNA profiles, where overexpression or underexpression of these molecules may offer insights into the disease.
Trial design
This completed study, designated as Phase NA, enrolled 57 participants. The trial investigated conditions including Pancreatic Adenocarcinoma. The study aimed to analyze the impact of tissue micro-RNA profiles obtained from EUS-FNA samples in pancreatic adenocarcinoma, contributing to a more personalized approach to treatment by understanding the molecular characteristics of the disease.
Key results
The trial reported key measurements related to survival in patients with pancreatic adenocarcinoma:
- For the outcome titled "Survival in Patients With Pancreatic Adenocarcinoma According to Tissue microRNA Expression" in the group "Patients With Solid Pancreatic Masses", the mean survival was reported as 8.3 months (Standard Deviation 7.526).
What this means
The posted results provide specific survival data for patients with pancreatic adenocarcinoma, linked to tissue microRNA expression. The reported mean survival of 8.3 months, with a standard deviation of 7.526 months, offers a baseline measurement for this patient group. While the data does not include comparative analyses or statistical significance, this measurement contributes to the understanding of prognostic factors in pancreatic adenocarcinoma and highlights the potential role of tissue micro-RNA profiling in assessing patient outcomes.
Source
The information regarding these trial results was obtained from ClinicalTrials.gov, a public database of clinical studies. The results for the study NCT04765410, titled "The Impact Of Tissue Micro-RNA Profile From EUS-FNA In Pancreatic Adenocarcinoma", were posted on 2026-04-16 on clinicaltrials.gov.